Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Cancer Chemoprevention
Accompanying CD-ROM in pocket at end of v. 2 contains a compact e-book version of v. 2.
Cancer Chemoprevention
Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated ge...
Transforming Growth Factor-Beta in Cancer Therapy, Volume II
Transforming Growth Factor- ß in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ß (TGF- ß) in cancer treatment and therapy. The second volume, Cancer Treatment in Therapy, is divided into three parts. The companion volume details the role of TGF- ß on basic and clinical biology.
Transforming Growth Factor-Beta in Cancer Therapy, Volume I
Transforming Growth Factor- ß in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ß (TGF- ß) in cancer treatment and therapy. The first volume, Basic and Clinical Biology, is divided into three parts. This volume’s companion, Cancer Treatment in Therapy, examines transforming growth factor- ß in other developing and advanced cancers and methods of treatment and therapy.
EGFR Signaling Networks in Cancer Therapy
The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies. Over decades of study, the EGF receptor structure, its ligand binding domains, the physical biochemistry underlying its intrinsic tyrosine kinase catalytic function and the modular interactions with SH2, PTB, and SH3 domain containing signaling adaptor p- teins required for signal transduction, have been extensively dissected. Not only is the EGF receptor the nexus of many streams of information, but it also forms one part of a c...
Bone Metastasis
Annotation Most of the morbidity and mortality associated with malignant disease arise from metastases rather than primary tumors. Patients with advanced breast or prostate cancers usually develop bone metastases; at the time of death the skeleton often bears the bulk of their tumor burden. This book covers the latest advances in understanding the molecular mechanisms underlying the pathophysiology of bone metastasis that are now driving the development of new therapeutic strategies, as exemplified by the successful use of bisphosphonates for metastatic bone disease.
The Oncogenomics Handbook
"In The Oncogenomics Handbook, a panel of internationally recognized researchers and clinicians provides an integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following that path, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development." --Résumé de l'éditeur.
Histone Deacetylases
Histone deacetylase 1 / Dominique Meunier and Christian Seiser -- Biochemistry of multiprotein HDAC complexes / Alejandro Vaquero, Michael Scher, and Danny Reinberg -- The biology of HDAC3 / Edward Seto -- The biology of HDAC8, a unique class I histone deacetylase / David Waltregny and Vincent Castronovo -- Regulation of muscle gene expression by histone deacetylases / Timothy A. McKinsey and Eric N. Olson -- The class IIA histone deacetylases: functions and regulation / Herbert G. Kasler and Eric Verdin -- Histone deacetylases in the response to misfolded proteins / J. Andrew McKee and Tso-Pang Yao -- Evolution of sirtuins from archaea to vertebrates / Roy A. Frye -- Structure of the Sir2 f...
Camptothecins in Cancer Therapy
A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.
Death Receptors in Cancer Therapy
An in depth review of our latest understanding of the molecular events that regulate cell death and those molecules that provide targets for developing agonists or antagonists to modulate death signaling for therapeutic purposes. The authors focus on the extrinsic system of death receptors, their regulation and function, and their abnormalities in cancer. Topics of particular interest include resistance to apoptosis, TRAIL signaling, death receptors in embryonic development, mechanisms of caspase activation, and death receptor mutations in cancer. Additional chapters address death signaling in melanoma, synthetic retinoids and death receptors, the role of p53 in death receptor regulation, immune suppression of cancer, and combination therapy with death ligands.
